Ignite Creation Date:
2024-05-05 @ 11:57 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00186628
Status:
COMPLETED
Last Update Posted:
2017-11-28
First Post:
2005-09-14
Brief Title:
Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD
Sponsor:
Stanford University
Organization:
Stanford University
Organization Data
Organization:
Stanford University
Class:
OTHER
Study ID:
IRB-02372
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Stanford University
Lead Sponsor Class:
OTHER
Responsible Party:
David Miklos
Responsible Party Title:
Assistant Professor of Medicine
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Stanford University
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| National Cancer Institute NCI | NIH |
| The Leukemia and Lymphoma Society | OTHER |